These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 15255529)

  • 1. Patents and investors.
    Carter S
    Med Device Technol; 2004 Apr; 15(3):11. PubMed ID: 15255529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 3. Filters for preparing to meet a venture capitalist.
    Christoffersen R
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE49-50. PubMed ID: 12874981
    [No Abstract]   [Full Text] [Related]  

  • 4. Convincing a venture capitalist to invest in your idea.
    Dooley JF; Dooley JF
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE45-8. PubMed ID: 12874980
    [No Abstract]   [Full Text] [Related]  

  • 5. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 6. Investing in nanotechnology.
    Paull R; Wolfe J; Hébert P; Sinkula M
    Nat Biotechnol; 2003 Oct; 21(10):1144-7. PubMed ID: 14520393
    [No Abstract]   [Full Text] [Related]  

  • 7. European markets target foreign biotechs.
    Louët S
    Nat Biotechnol; 2003 Jul; 21(7):719. PubMed ID: 12833075
    [No Abstract]   [Full Text] [Related]  

  • 8. Companies jostle for access to public markets.
    Bouchie A
    Nat Biotechnol; 2003 Dec; 21(12):1413-4. PubMed ID: 14647309
    [No Abstract]   [Full Text] [Related]  

  • 9. Biotechs await single European financial market.
    Louët S
    Nat Biotechnol; 2003 Dec; 21(12):1417. PubMed ID: 14647312
    [No Abstract]   [Full Text] [Related]  

  • 10. Cash-strapped biotechs find financing alternative.
    Mitchell P
    Nat Biotechnol; 2004 Sep; 22(9):1057-8. PubMed ID: 15340452
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotech IPOs: handle with care.
    Jacobs T
    Nat Biotechnol; 2003 Dec; 21(12):1437. PubMed ID: 14647322
    [No Abstract]   [Full Text] [Related]  

  • 12. The term sheet tango.
    Willey T; Parsigian D
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE29-30. PubMed ID: 12874974
    [No Abstract]   [Full Text] [Related]  

  • 13. Shareholders flex their muscles.
    Thiel K
    Nat Biotechnol; 2008 Jan; 26(1):19-21. PubMed ID: 18183007
    [No Abstract]   [Full Text] [Related]  

  • 14. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 15. My worst biotech investment.
    Jacobs T
    Nat Biotechnol; 2006 Apr; 24(4):401. PubMed ID: 16601718
    [No Abstract]   [Full Text] [Related]  

  • 16. Biotechs for pennies?
    Jacobs T
    Nat Biotechnol; 2004 Dec; 22(12):1509. PubMed ID: 15583652
    [No Abstract]   [Full Text] [Related]  

  • 17. Public markets show signs of life.
    Mitchell P
    Nat Biotechnol; 2003 Aug; 21(8):833-4. PubMed ID: 12894181
    [No Abstract]   [Full Text] [Related]  

  • 18. The rise of European venture capital for biotechnology.
    Howell M; Trull M; Dibner MD
    Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356
    [No Abstract]   [Full Text] [Related]  

  • 19. This means war.
    Nat Biotechnol; 2008 Sep; 26(9):954. PubMed ID: 18779784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UK bidding war amidst merger mania.
    Mitchell P
    Nat Biotechnol; 2003 Apr; 21(4):343-4. PubMed ID: 12665805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.